Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

15 Apr 2025 15:30

RNS Number : 1532F
GSK PLC
15 April 2025
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025, on Ordinary Shares held within an ISA

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£ 12.7300

25

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2025-04-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 April 2025, on Ordinary Shares held within an ISA

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£ 12.7300

22

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2025-04-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFFFLIEISEEL
Date   Source Headline
18th Sep 20257:00 amRNSTransaction in Own Shares
17th Sep 20257:00 amRNSGSK US Investment Announcement
17th Sep 20257:00 amRNSTransaction in Own Shares
16th Sep 20257:00 amRNSTransaction in Own Shares
15th Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSTransaction in Own Shares
11th Sep 20257:00 amRNSTransaction in Own Shares
10th Sep 20253:30 pmRNSDirector/PDMR Shareholding
10th Sep 20257:00 amRNSTransaction in Own Shares
9th Sep 20257:00 amRNSTransaction in Own Shares
8th Sep 20257:00 amRNSTransaction in Own Shares
5th Sep 20257:00 amRNSTransaction in Own Shares
4th Sep 20253:30 pmRNSDirector/PDMR Shareholding
4th Sep 20257:00 amRNSTransaction in Own Shares
3rd Sep 20257:00 amRNSTransaction in Own Shares
2nd Sep 20257:00 amRNSTransaction in Own Shares
1st Sep 20253:00 pmRNSTotal Voting Rights
1st Sep 20257:00 amRNSTransaction in Own Shares
29th Aug 20257:00 amRNSTransaction in Own Shares
28th Aug 20257:00 amRNSTransaction in Own Shares
27th Aug 20257:00 amRNSTransaction in Own Shares
26th Aug 20257:00 amRNSTransaction in Own Shares
22nd Aug 20257:00 amRNSTransaction in Own Shares
21st Aug 20253:30 pmRNSDirector/PDMR Shareholding
21st Aug 20257:00 amRNSTransaction in Own Shares
20th Aug 20257:00 amRNSTransaction in Own Shares
19th Aug 20253:30 pmRNSDirector/PDMR Shareholding
19th Aug 20257:00 amRNSTransaction in Own Shares
18th Aug 20257:00 amRNSTransaction in Own Shares
15th Aug 20257:00 amRNSTransaction in Own Shares
14th Aug 20257:00 amRNSTransaction in Own Shares
13th Aug 20257:00 amRNSTransaction in Own Shares
12th Aug 20253:30 pmRNSDirector/PDMR Shareholding
12th Aug 20257:00 amRNSTransaction in Own Shares
11th Aug 20257:00 amRNSFDA to review gonorrhea indication for gepotidacin
11th Aug 20257:00 amRNSTransaction in Own Shares
8th Aug 20257:00 amRNSCureVac/BioNTech mRNA patent litigation settlement
8th Aug 20257:00 amRNSTransaction in Own Shares
7th Aug 20257:00 amRNSTransaction in Own Shares
6th Aug 20257:00 amRNSTransaction in Own Shares
5th Aug 20257:00 amRNSTransaction in Own Shares
4th Aug 20257:00 amRNSTransaction in Own Shares
1st Aug 20253:00 pmRNSTotal Voting Rights
1st Aug 20257:00 amRNSTransaction in Own Shares
31st Jul 20257:00 amRNSTransaction in Own Shares
30th Jul 20257:05 amRNSTransaction in Own Shares
30th Jul 20257:00 amRNS2nd Quarter Results
29th Jul 20257:00 amRNSTransaction in Own Shares
28th Jul 20257:00 amRNSGSK enters Hengrui Pharma collaboration agreements
28th Jul 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.